tbuckley/cabot-search huggingface dataset:
P163 Surgical lung biopsy in the diagnosis of interstitial lung disease- a systematic literature review
Authors: TA Mikolasch, A Marshall, A Salam, JC Porter
Journal: Thorax (2016)

<h3>Methods</h3> We performed a systematic literature review based on the PRISMA guidelines following a pre-specified protocol. Pubmed and Embase databases were searched for studies reporting the use of Surgical Lung Biopsies (SLB) in the diagnosis of adults with Interstitial Lung Disease (ILD). Randomised controlled trials, case control studies and case series with more than 20 subjects were included, restricted to papers published from 2000 till September 2015 taking into consideration changes in surgical techniques and diagnostic criteria. All relevant abstracts were assessed by two independent reviewers utilising EPPI reviewer 4, an online software tool for research synthesis. Full papers were obtained for those deemed potentially eligible, and two reviewers agreed the final set of review papers. Primary outcomes were 90 day mortality and complications while secondary were diagnostic yield, mean length of stay and change of treatment following biopsy. <h3>Results</h3> (see Figure 1). 24 studies were included reporting on the use of SLB in 2600 patients. The overall quality of the reports was moderate to poor with mainly retrospective case series available. Mean mortality was 4.9% (CI 90% −0.04 −0.14) with a wide range of 0 – 22.4%. Complication rates were reported in 19 of the studies. Mean overall complication rate was 19.4% (CI −0.05 – 0.48) with a range from 7.1% to 65.7%. Mean length of stay adjusted for patient numbers was 5.4 days and diagnostic yield for definite pathological diagnosis was 89%. Eight studies recorded treatment change following SLB in a total of 588 patients out of 869. Mean percentage of patients in whom treatments was changed on the basis of the SLB result was 60% (CI 90% 0.35–0.87). <h3>Conclusions</h3> High-quality data on the outcomes of SLB in ILD diagnosis are sparse. Comparison between different studies is difficult due to heterogeneous patient populations (e.g. acute vs elective cases) and differences in outcome reporting. Nonetheless, the overall mortality and morbidity rates are similar to a recent analysis of a US national database. SLB in ILD remains a useful diagnostic tool but carries significant mortality and morbidity. More prospective data and evaluation of surgical risk stratification is required.
Control of In Vivo Contraction/Relaxation Kinetics by Myosin Binding Protein C
Authors: Takahiro Nagayama, Eiki Takimoto, Sakthivel Sadayappan, James O. Mudd, J.G. Seidman, Jeffrey Robbins, David A. Kass
Journal: Circulation (2007)

Background— Cardiac myosin binding protein-C (cMyBP-C) is a thick-filament protein whose presence and phosphorylation by protein kinase A (PKA) regulates cross-bridge formation and kinetics in isolated myocardium. We tested the influence of cMyBP-C and its PKA-phosphorylation on contraction/relaxation kinetics in intact hearts and revealed its essential role in several classic properties of cardiac function. Methods and Results— Comprehensive in situ cardiac pressure–volume analysis was performed in mice harboring a truncation mutation of cMyBP-C (cMyBP-C (t/t) ) that resulted in nondetectable protein versus hearts re-expressing solely wild-type (cMyBP-C WT:(t/t) ) or mutated protein in which known PKA-phosphorylation sites were constitutively suppressed (cMyBP-C AllP-:(t/t) ). Hearts lacking cMyBP-C had faster early systolic activation, which then terminated prematurely, limiting ejection. Systole remained short at faster heart rates; thus, cMyBP-C (t/t) hearts displayed minimal rate-dependent decline in diastolic time and cardiac preload. Furthermore, prolongation of pressure relaxation by afterload was markedly blunted in cMyBP-C (t/t) hearts. All 3 properties were similarly restored to normal in cMyBP-C WT:(t/t) and cMyBP-C AllP-:(t/t) hearts, which supports independence of PKA-phosphorylation. However, the dependence of peak rate of pressure rise on preload was specifically depressed in cMyBP-C AllP-:(t/t) hearts, whereas cMyBP-C (t/t) and cMyBP-C AllP-:(t/t) hearts had similar blunted adrenergic and rate-dependent contractile reserve, which supports linkage of these behaviors to PKA-cMyBP-C modification. Conclusions— cMyBP-C is essential for major properties of cardiac function, including sustaining systole during ejection, the heart-rate dependence of the diastolic time period, and relaxation delay from increased arterial afterload. These are independent of its phosphorylation by PKA, which more specifically modulates early pressure rise rate and adrenergic/heart rate reserve.
ADMINISTRATION OF ARSPHENAMIN IN THE TROPICS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P2.02-028 A Phase I/II Study of Carboplatin, Pemetrexed, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC. CJLSG0912
Authors: Naohiko Murata, Masashi Kondo, Chiyoe Kitagawa, Hideo Saka
Journal: Journal of Thoracic Oncology (2017)
P3.02b-114 Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience
Authors: Fran Seiwerth, Lela Bitar, Ivona Markelić, Fedza Dzubur, Luka Brcic, Sven Seiwerth, Marija Misic, Mihovil Roglić, Sanja Plestina, Branka Čučević, Suzana Kukulj, Silvana Smojver-Jezek, Miroslav Samarzija, Marko Jakopovic
Journal: Journal of Thoracic Oncology (2017)
P217 Improving care and support in advanced copd – six recommendations from the population-based living with breathlessness study
Authors: MC Farquhar, G Ewing, P White, P Burge, R Mahadeva, AC Gardener, C Moore, S Howson, S Booth, C Saunders, T Ling
Journal: Thorax (2016)

<h3>Introduction</h3> Chronic obstructive pulmonary disease (COPD) is a chronic life-limiting condition with high symptom-burden and carer-burden. National guidance on end of life care calls for quality care for patients with any condition, yet we rely on frameworks developed for cancer with its largely predictable trajectory. <h3>Aim</h3> To develop evidence-based recommendations to inform a new framework to improve care and support of patients living with advanced COPD and their informal carers. <h3>Methods</h3> The Living with Breathlessness Study was a multiple-component, population-based, mixed-method longitudinal, multiple-perspective research programme to identify new evidence on health and social care needs and preferences of patients with advanced COPD and their carers. It followed more than 500 patients and carers for up to 18-months through interview and survey methods. Qualitative data on barriers and facilitators to meeting needs were collected from clinicians. Programme-wide evidence was synthesised to identify recommendations. Stakeholder views were then collected through a workshop and online survey. <h3>Results</h3> Six inter-related recommendations emerged, linked by the concept of proactive person-centred care: (1) Stop the continual focus on the challenge of prognosis and unpredictability of trajectories as barriers to meeting needs, (2) Change targets to incentivise person-centred care within existing services, (3) Enable identification and response to patient support needs (through evidence-based tools and approaches), (4) Identify and support patients’ informal carers (through evidence-based tools and approaches), (5) Identify and respond to psychological morbidity in patients and informal carers identify and respond to psychological morbidity, (6) Change societal attitudes and understandings of COPD, breathlessness, palliative care and informal carer support. The recommendations are underpinned by action points to enable delivery. The recommendations garnered significant support from stakeholders, with caution regarding ease of implementation which varied by recommendation. <h3>Conclusion</h3> These six inter-related recommendations, and supporting action points, could inform a new framework for care and support in advanced COPD likely to have resonance for those living with other advanced non-malignant long term conditions, and for clinicians striving to support them.
Topical ivermectin improves allergic skin inflammation
Authors: E. Ventre, A. Rozières, V. Lenief, F. Albert, P. Rossio, L. Laoubi, D. Dombrowicz, B. Staels, L. Ulmann, V. Julia, E. Vial, A. Jomard, F. Hacini‐Rachinel, J.‐F. Nicolas, M. Vocanson
Journal: Allergy (2017)

Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties.Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays.Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation.Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.
Abstract A10: Redox regulation of the Wnt/β-catenin pathway in colorectal cancer
Authors: Alex Campos, Brian James, Petrus De Jong, Garth Powis
Journal: Clinical Cancer Research (2017)

Abstract Colorectal cancer (CRC) is the third most newly diagnosed cancer, and the third most frequent cause of cancer related death in the United States. Thus, there is an urgent unmet need for the development of new therapies for the treatment of CRC. Loss of function mutations in adenomatous polyposis coli (APC), a critical member of the β-catenin destruction complex, lead to elevated protein levels of β-Catenin, and are found in 85% of CRCs, where they are associated with decreased CRC patient survival. Increased levels of β-catenin protein augment the nuclear accumulation of β-catenin where it interacts with transcription factors to induce transcription of target genes promoting cell proliferation, survival, and migration. Currently, there is still no effective therapy targeting aberrant β-catenin transcriptional activity. Here we report on the redox dependency of the Wnt/β-catenin signaling pathway, identified through a forward genetic screen in Drosophila, and identify TxnR1 as a potential target for the inhibition of aberrant β-catenin transcriptional activity through in vivo studies with the APCmin/+ mouse model. Drosophila harboring a mutation in the thioredoxin reductase (txnr1) gene that have a partial lethality phenotype were used in an enhancer/suppressor forward genetic screen. Increased lethality was observed when the txnr1 mutation (Txnr1481) was combined with heterozygous mutations and deletions in dwnt2, while dwnt2 deletion and mutations alone had no effect (on lethality). In addition, β-Catenin mediated transcription, as measured by TOP Flash luciferase assay, was diminished when TxnR1 was silenced by siRNA. To test the translational value of these findings, APCmin/+ mice were treated with PX-12, a human TxnR1 inhibitor, daily by gavage from day 40 to time of death. We observed a dose dependent reduction in the number and size of intestinal polyps by PX-12 treatment, and an increased survival in treated mice. Also, human colorectal cancer cell lines treated with PX-12 displayed attenuated phosphorylation of β-catenin serine residues 552 and 675. These results suggest a conserved mechanism for the redox regulation of the Wnt/β-catenin pathway involving TxnR1; furthermore, inhibition of TxnR1 can inhibit intestinal neoplasia development in an experimental model of CRC. Citation Format: Alex Campos, Brian James, Petrus De Jong, Garth Powis. Redox regulation of the Wnt/β-catenin pathway in colorectal cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A10.
P1.06-044 Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France
Authors: Christos Chouaid, Delphine Loirat, Chloé Godard, Emilie Clay, Aurélie Millier, Laurie Lévy-Bachelot, Eric Angevin
Journal: Journal of Thoracic Oncology (2017)
Comparison of two major intergroup induction intensive regimens in Hispanic adolescent and young adults (AYA) with acute lymphocytic leukemia (ALL): The importance of a complete molecular response.
Authors: Carlos Enrique Vigil, Lorena Escalante, Lourdes Lopez, Marco Villena, Shirley Quintana, Cesar Augusto Samanez, Luis Augusto Casanova
Journal: Journal of Clinical Oncology (2013)

7072 Background: Novel intensive chemotherapy regimens impacted in the prognosis of adolescent and young adult pts with ALL. The application of pediatric inspired therapies demonstrated complete response reported to be &gt; 80%, and long-term survival rates range from 30% to 45%. In the past, ALL treatments had been designed on the presence of risk factors as elevated WBC, time to complete remission or immunophenotype. Recently, MRD monitoring had risen as a risk predictor. Hypothesis: Complete response(CR) associated with a CMR has impact in disease-free survival. Methods: Between March&gt; 2010 and November 2012, 101 adolescent and young adult pts were diagnosed and treated for (Ph)–negative ALL with the C10403 intergroup protocol (N=47) and the 2008 Spanish PETHEMA regimen (N=54). The residual disease status was assessed after induction by multiparametric flow cytometry (MRD &lt;0.1%). Results: The median age of the pts was 17.56 years (range, 14-24); with 69 pts (68%) ≤ 18 year-old. 27 (26.7%) pts were WBC ≥ 50x10 9 /L, 63 pts (62%) B immunophenotype, cytogenetics was unknown in 69 pts. After the induction, the CR was achieved in 81% vs 79.6% pts ( Int C10403 vs Pethema, respectively ). The induction mortality rate was 0% vs 7%. Slow responders to induction chemotherapy were 23.81% and 28.8% respectively (p=0.591). A CMR (CR+MRD ≤0.1%) was seen on 70.21% vs 63.27%. The kaplan-meier 2-year disease free-survival rate calculated for CMR patients on C10403 was 35% vs 17% for the Pethema, which was statistically significant (p&lt; 0.04). A multivariate analysis of pts characteristics in CMR could not identified risk factors for disease prognosis. Conclusions: Two different regimens C10403 vs Pethema, could not demonstrate a statistic difference in morphological CR. Lately,the addition of minimal residual disease ≤0.1% (MRD) in the analysis, demonstrated a plausible monitoring variable of response. We suggest that a CMR (CR +MRD at induction) could be a new standard variable to assess responses regardless of previous risk categories. Further validation may be mandatory.
Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant
Authors: Carlo Visco, Renato Zambello, Rossella Paolini, Silvia Finotto, Roberta Zanotti, Francesco Zaja, Gianpaolo Nadali, Livio Trentin, Elisabetta Rodella, Laura Lissandrini, Gianpietro Semenzato, Giovanni Pizzolo, Francesco Rodeghiero
Journal: Blood (2011)
First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.
Authors: William Ershler, Jennifer Tam, Veena Charu, Ali Ben-Jacob, Seta Shahin, Jeannette Green, Roger Dansey, Lodovico Balducci
Journal: Blood (2005)
P18 Do bronchial washings improve diagnostic yield in patients undergoing ebus-tbna
Authors: K Srikanthan, C Drouot, C Smyth, T Giles, M Walshaw, K Mohan
Journal: Thorax (2016)

<h3>Introduction</h3> EBUS is increasingly used in the diagnosis and staging of lung cancer, particularly where there are no endobronchial lesions. Despite this, in these cases referring physicians often request bronchial washings to be performed at the same time, in the hope of increasing diagnostic yield. We wished to investigate whether this added to the information provided by EBUS-TBNA in such patients. <h3>Methods</h3> We looked at all patients who underwent EBUS procedures at our tertiary centre in the last six months, who also had washings taken for cytology at the same sitting where there were no visible endobronchial lesions. We compared the diagnostic yield from EBUS-TBNA with that from the bronchial washings. <h3>Results</h3> Of the 111 EBUS patients, 40 underwent concurrent bronchial washings for cytology (mean age 70 years (range 23–89), 23 (58%) male). EBUS-TBNA samples were diagnostic in 39 (98%): 31 malignancy (12 adenocarcinoma, 11 squamous cell carcinoma, 3 small cell carcinoma, 2 carcinoid, 2 breast adenocarcinoma, 1 renal cell carcinoma] and 8 were benign disease. Although bronchial washings were also diagnostic for malignancy in 7 (18%) (4 squamous cell carcinoma, 3 adenocarcinoma), all these cases also had positive EBUS-TBNA samples. There were no cases in which bronchial washings provided the diagnosis in the context of a negative EBUS-TBNA sample. <h3>Conclusions</h3> This is the first study to evaluate the effectiveness of bronchial washings in addition to EBUS-TBNA sampling, where there is no visible endobronchial disease. Since each cytological sample analysis costs £75, elimination of bronchial washings in our patients could have saved £3000 over this 6-month period. We conclude that in those patients undergoing EBUS-TBNA, who also have peripheral pulmonary lesions, bronchial washings do not improve the diagnostic yield, and should not constitute routine practice.
High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience.
Authors: Kai Neben, Julia Meissner, Sascha Dietrich, Manfred Hensel, Alwin Krämer, Mathias Witzens-Harig, Peter Dreger, Anthony D. Ho
Journal: Blood (2008)
Comparison of Uptake and Intracellular Induced Structural Changes of Arsenic Trioxide, an Inorganic Compound, and Organic Arsenic Derivative S-Dimethylarsino-Glutathione (SGLU; ZIO-101) in NB4 Acute Promyelocytic Leukemia (APL) Cells.
Authors: Taghi Manshouri, Subbarao V. Kala, Faramarz Ashoori, Ralph Zingaro, Emil J. Freireich, Michael Andreeff, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2005)
MSDD1, a Prodrug of 5-Hydroxymethyl-2-Furfural (5HMF), Prolongs the Antisickling Effect of 5HMF in Transgenic Sickle Mice.
Authors: Osheiza Abdulmalik, Martin K. Safo, Richmond Danso-Danquah, Jisheng Yang, Qiukan Chen, Carlo Brugnara, Donald J. Abraham, Toshio Asakura
Journal: Blood (2004)
A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML
Authors: Jorge Cortes, Gail J. Roboz, Hagop M. Kantarjian, Eric J. Feldman, Judith E. Karp, Keith W. Pratz, Niranjan S. Rao, Shiro Akinaga, Mark J. Levis
Journal: Blood (2008)
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC
Authors: Hatim Husain, Renato Martins, Sarah Goldberg, Peggy Senico, Wendy Ma, Joanna Masters, Nuzhat Pathan, Dong-Wan Kim, Mark Socinski, Zelanna Goldberg, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2017)
Intracellular Recycling and Iron Donating Ability of Transferrin Receptor 2α Protein Expressed in Transferrin Receptor-Deficient Chinese Hamster Ovary Cells.
Authors: Katsuya Ikuta, Junko Jimbo, Takaaki Hosoki, Motohiro Shindo, Kazuya Sato, Yoshihiro Torimoto, Yutaka Kohgo
Journal: Blood (2007)
P46 Assessment of aortic stiffness and correlation with lung function in patients with copd using cardiac magnetic resonance
Authors: E De Garate, G Biglino, A Wilson, E Baker, P Jones, C Bucciarelli-Ducci, J Dodd
Journal: Thorax (2016)

<h3>Introduction:</h3> COPD has been associated with increased cardiovascular risk, although the mechanisms for this are still unclear. Proposed theories include increased systemic inflammation and accelerated ageing resulting in arterial stiffness. We aimed to evaluate aortic distensibility using cardiac MRI in patients with COPD compared to an age-matched non COPD, ‘healthy’ smoker control group. <h3>Methods</h3> we recruited 49 subjects, of which 27 had diagnosis of COPD and FEV1/FVC &lt; 70%; and 21 age-matched normal smoker controls (mean age 64 years ± 10). We acquired data including age, gender, smoking status, number of packs of cigarettes per year, and FEV1/FVC ratio. MRI images were acquired using a 3.0T scanner, and analysed using CVI42 software. Left ventricle and right ventricle function and volumes were evaluated using short axis SSFP cine. Aortic distensibility was measured using a validated method that takes in consideration aortic maximal and minimal areas from axial SSFP cine acquired perpendicular to the vessel. <h3>Results</h3> Aortic distensibility was reduced in the COPD patients compared to control (0.0022610 × 10<sup>−3</sup> mm Hg <sup>−1</sup> vs 0.004337 × 10<sup>−3</sup> mm Hg<sup>−1</sup>, p = 0.003). The distensibility of descending aorta was similar in both groups (p = 0.06). Ejection fraction and biventricular volumes were also similar in the two groups. Univariant analysis demonstrated a significant relationship between ascending aorta distensibility and FEV1/FVC ratio. There was no difference when comparing distensibility with smoking status or number of packs per year. Linear regression demonstrated that the degree of aortic distensibility was directly proportional to FEV1/FVC ratio <h3>Conclusion</h3> Patients with COPD have significantly increased aortic stiffness measured by cardiac magnetic resonance. This was observed in the presence of normal LV/RV systolic function in both groups. This difference was related to FEV1/FVC, and was independent of smoking. Preserved FEV1/FVC showed more elastic ascending aortas. Reduced aortic distensibility could represent the early phase changes in cardiovascular function but further research is needed.
切除不能な第III期非小細胞肺癌(NSCLC)に対するマイトシン/ビンデシン/シスプラチン(MVP)対毎週のイリノテカン/カルボプラチン(PC)同時併用胸部放射線療法(TRT)の無作為第III相試験:WJTOG0105
Authors: Yoshida K, Uejima H, Satouchi M, Kudoh S, Nakagawa K, Hida T, Kawahara M, Sugiura T, Tamura K, Fukuoka M
Journal: Journal of Thoracic Oncology (2007)
P2.01-061 Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas
Authors: Edwin Parra, Pamela Villalobos, Jiexin Zhang, Carmen Behrens, Barbara Mino, Cesar Moran, Stephen Swisher, Boris Sepesi, Annika Weissferdt, Neda Kalhor, John Heymach, Jack Lee, Jianjun Zhang, Don Lynn Gibbons, Jaime Rodrigues-Canales, Ignacio Wistuba
Journal: Journal of Thoracic Oncology (2017)